Skip Navigation LinksHome > December 2011 - Volume 17 - Issue > Open Label Ustekinumab for the treatment of anti‐TNFα refrac...
Inflammatory Bowel Diseases:
Clinical Poster Presentations

Open Label Ustekinumab for the treatment of anti‐TNFα refractory moderate‐to‐severe Crohn's disease: Follow up of a cohort of patients at an academic inflammatory bowel disease center: P‐4.

Rosen, Melissa; Scherl, Ellen; Bosworth, Brian

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login